Skip to content

Research / Diseases

Amyotrophic Lateral Sclerosis

ALS is also known as Lou Gehrig’s disease, or motor neuron disease.

Dr. Rachael Dunlop and Christofer Noverola at the automated sample-handling robot in the Brain Chemistry Labs laboratory
Section 01The problem

It can take more than 12 months to get an ALS diagnosis[1]. During this time, patients are shuttled between doctors and may even undergo unnecessary surgeries[2] or other invasive interventions. This adds to the financial burden and associated anxiety for patients living with worsening symptoms and no definitive diagnosis. As many as 63% of patients also receive an incorrect diagnosis in the early stages[3].

ALS is currently diagnosed by careful clinical examination using electromyography (EMG) and nerve conduction studies to detect signs of motor neuron degeneration, together with MRI and blood tests to rule out other conditions. But given the similarity of symptoms to other diseases, particularly in the early stages, physicians sometimes require symptom progression to definitively determine ALS as the culprit. This is especially important given an ALS diagnosis is generally terminal. However, survival time from diagnosis averages 2 to 5 years, so patients do not have time to wait around.

Section 02The need

There is an urgent need for a rapid, accurate, and affordable diagnostic test for ALS. This would transform patient care and improve outcomes in several ways:

  • Patients could access therapies sooner, when drugs are more effective.
  • Patients could get earlier access to clinical trials, when experimental interventions are more likely to modify disease progression.
  • Patients could avoid unnecessary medical interventions, misdiagnoses, and the anxiety of "not knowing."
Section 03Our work

At Brain Chemistry Labs, we are working on a blood test for ALS designed to work in concert with a doctor’s assessment of a patient’s symptoms, as an aid to early diagnosis. The test is based on a unique genetic fingerprint that differentiates people with ALS from healthy controls.

Our ALS test has been validated in a commercial lab as a CLIA/CAP laboratory-developed test.

See our related publications

Section 04References
  1. 1.

    Goyal NA, Bonar K, Savic N, Beau Lejdstrom R, Wright J, Mellor J, et al. Misdiagnosis of amyotrophic lateral sclerosis in clinical practice in Europe and the USA: a patient chart review and physician survey. Amyotroph Lateral Scler Front Degener. 2024;25:16–25. doi:10.1080/21678421.2023.2260808

  2. 2.

    Srinivasan J, Scala S, Jones HR, Saleh F, Russell JA. Inappropriate surgeries resulting from misdiagnosis of early amyotrophic lateral sclerosis. Muscle Nerve. 2006;34:359–60. doi:10.1002/mus.20555

  3. 3.

    Richards D, Morren JA, Pioro EP. Time to diagnosis and factors affecting diagnostic delay in amyotrophic lateral sclerosis. J Neurol Sci. 2020;417:117054. doi:10.1016/j.jns.2020.117054

Status

Validated

Validated in a commercial laboratory as a CLIA/CAP laboratory-developed test.

  • SampleBlood test
  • BasisGenetic fingerprint
  • RoleAid to early diagnosis
The road to this test
Section 05How the ALS Test works

From a blood draw to a referral.

Circulating RNA are captured from the sample, their microRNA is read, and a fingerprint of markers separates ALS from healthy controls. The result goes to the physician as an aid to diagnosis.

The papers behind it
BLOOD INOne small draw01CIRCULATING RNACaptured from the sample02MICRORNA FINGERPRINTEight markers, read together03RESULT OUTReferral to a neurologist, sooner04